{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:09:41Z","timestamp":1792098581957,"version":"4.4.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"am","delay-in-days":360,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.molmed.2020.05.005","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:21:01Z","timestamp":1592439661000},"page":"819-832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Genetic and Genomic Mechanisms of Primary Aldosteronism"],"prefix":"10.1016","volume":"26","author":[{"given":"Fabio L.","family":"Fernandes-Rosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheerazed","family":"Boulkroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Christina","family":"Zennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2020.05.005_bb0005","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.molmed.2020.05.005_bb0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-0031-1295438","article-title":"Prevalence of primary aldosteronism in patient's cohorts and in population-based studies \u2013 a review of the current literature","volume":"44","author":"Hannemann","year":"2012","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.molmed.2020.05.005_bb0015","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2020.05.005_bb0020","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/HYPERTENSIONAHA.111.175083","article-title":"Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms)","volume":"58","author":"Mulatero","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0025","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","article-title":"Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study","volume":"62","author":"Savard","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.molmed.2020.05.005_bb0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.molmed.2020.05.005_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/joe.1.06017","article-title":"The new biology of aldosterone","volume":"186","author":"Connell","year":"2005","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.molmed.2020.05.005_bb0045","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1055\/s-0029-1243601","article-title":"TASK1 and TASK3 potassium channels: determinants of aldosterone secretion and adrenocortical zonation","volume":"42","author":"Bandulik","year":"2010","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.molmed.2020.05.005_bb0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mce.2003.10.011","article-title":"The regulation of aldosterone synthase expression","volume":"217","author":"Bassett","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.molmed.2020.05.005_bb0055","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.mce.2008.12.015","article-title":"Mechanisms of angiotensin II-mediated regulation of aldosterone synthase expression in H295R human adrenocortical and rat adrenal glomerulosa cells","volume":"302","author":"Szekeres","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.molmed.2020.05.005_bb0060","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mce.2011.07.034","article-title":"Acute and chronic regulation of aldosterone production","volume":"350","author":"Hattangady","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.molmed.2020.05.005_bb0065","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3346\/jkms.1998.13.6.629","article-title":"EGF-stimulated aldosterone secretion is mediated by tyrosine phosphorylation but not by phospholipase C in cultured porcine adrenal glomerulosa cells","volume":"13","author":"Kim","year":"1998","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.molmed.2020.05.005_bb0070","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1749-6632.2000.tb05428.x","article-title":"Possible function of IL-6 and TNF as intraadrenal factors in the regulation of adrenal steroid secretion","volume":"917","author":"Judd","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.molmed.2020.05.005_bb0075","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/bs.vh.2018.10.001","article-title":"Paracrine regulation of aldosterone secretion in physiological and pathophysiological conditions","volume":"109","author":"Lefebvre","year":"2019","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.molmed.2020.05.005_bb0080","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/355262a0","article-title":"A chimaeric 11beta-hydroxylase aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension","volume":"355","author":"Lifton","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2020.05.005_bb0085","doi-asserted-by":"crossref","first-page":"8327","DOI":"10.1073\/pnas.89.17.8327","article-title":"Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2","volume":"89","author":"Pascoe","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2020.05.005_bb0090","first-page":"1109","article-title":"Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone","volume":"95","author":"Sutherland","year":"1966","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.molmed.2020.05.005_bb0095","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ecl.2011.01.012","article-title":"Glucocorticoid-remediable aldosteronism","volume":"40","author":"Halperin","year":"2011","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.molmed.2020.05.005_bb0100","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1172\/JCI118279","article-title":"Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree","volume":"96","author":"Pascoe","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2020.05.005_bb0105","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/00004872-200018090-00002","article-title":"Primary aldosteronism: learning from the study of familial varieties","volume":"18","author":"Stowasser","year":"2000","journal-title":"J. Hypertens."},{"key":"10.1016\/j.molmed.2020.05.005_bb0110","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1126\/science.1198785","article-title":"K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension","volume":"331","author":"Choi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.molmed.2020.05.005_bb0115","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ng.2716","article-title":"Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension","volume":"45","author":"Azizan","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2020.05.005_bb0120","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/ng.2695","article-title":"Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism","volume":"45","author":"Scholl","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2020.05.005_bb0125","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ng.2550","article-title":"Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension","volume":"45","author":"Beuschlein","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.molmed.2020.05.005_bb0130","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/HYPERTENSIONAHA.114.03419","article-title":"Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma","volume":"64","author":"Fernandes-Rosa","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0135","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1530\/ERC-15-0321","article-title":"Novel somatic mutations and distinct molecular signature in aldosterone-producing adenomas","volume":"22","author":"Akerstrom","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.molmed.2020.05.005_bb0140","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2018-01004","article-title":"Targeted molecular characterization of aldosterone-producing adenomas in White Americans","volume":"103","author":"Nanba","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2020.05.005_bb0145","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1161\/HYPERTENSIONAHA.118.12070","article-title":"Genetic characteristics of aldosterone-producing adenomas in blacks","volume":"73","author":"Nanba","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0150","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/HYPERTENSIONAHA.119.14177","article-title":"Genetic, cellular, and molecular heterogeneity in adrenals with aldosterone-producing adenoma","volume":"75","author":"De Sousa","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0155","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.06315","article-title":"Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism","volume":"4","author":"Scholl","year":"2015","journal-title":"eLife"},{"key":"10.1016\/j.molmed.2020.05.005_bb0160","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ebiom.2016.10.002","article-title":"CACNA1H mutations are associated with different forms of primary aldosteronism","volume":"13","author":"Daniil","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.molmed.2020.05.005_bb0165","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41588-018-0053-8","article-title":"A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism","volume":"50","author":"Fernandes-Rosa","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2020.05.005_bb0170","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41588-018-0048-5","article-title":"CLCN2 chloride channel mutations in familial hyperaldosteronism type II","volume":"50","author":"Scholl","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2020.05.005_bb0175","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/HYPERTENSIONAHA.119.14349","article-title":"Somatic CACNA1H mutation as a cause of aldosterone-producing adenoma","volume":"75","author":"Nanba","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0180","doi-asserted-by":"crossref","first-page":"K37","DOI":"10.1530\/EJE-19-0377","article-title":"A somatic mutation in CLCN2 identified in a sporadic aldosterone-producing adenoma","volume":"181","author":"Dutta","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.molmed.2020.05.005_bb0185","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1210\/en.2012-1241","article-title":"The potassium channel, Kir3.4 participates in angiotensin II-stimulated aldosterone production by a human adrenocortical cell line","volume":"153","author":"Oki","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmed.2020.05.005_bb0190","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1097\/HJH.0b013e328356139f","article-title":"Characterization of a novel somatic KCNJ5 mutation delI157 in an aldosterone-producing adenoma","volume":"30","author":"Murthy","year":"2012","journal-title":"J. Hypertens."},{"key":"10.1016\/j.molmed.2020.05.005_bb0195","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1210\/jc.2014-3009","article-title":"Novel KCNJ5 mutations in sporadic aldosterone-producing adenoma reduce Kir3.4 membrane abundance","volume":"100","author":"Cheng","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.molmed.2020.05.005_bb0200","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1161\/HYPERTENSIONAHA.119.13476","article-title":"Primary aldosteronism: KCNJ5 mutations and adrenocortical cell growth","volume":"74","author":"Yang","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0205","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/HYPERTENSIONAHA.111.186239","article-title":"Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas","volume":"59","author":"Azizan","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0210","doi-asserted-by":"crossref","first-page":"E1089","DOI":"10.1210\/jc.2015-2149","article-title":"A meta-analysis of somatic KCNJ5 K(+) channel mutations in 1636 patients with an aldosterone-producing adenoma","volume":"100","author":"Lenzini","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2020.05.005_bb0215","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1210\/jc.2011-2885","article-title":"Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas","volume":"97","author":"Taguchi","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2020.05.005_bb0220","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1161\/HYPERTENSIONAHA.114.03346","article-title":"Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma","volume":"65","author":"Zheng","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0225","doi-asserted-by":"crossref","first-page":"e708","DOI":"10.1097\/MD.0000000000000708","article-title":"Prevalence and characterization of somatic mutations in Chinese aldosterone-producing adenoma patients","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.molmed.2020.05.005_bb0230","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/HYPERTENSIONAHA.111.186478","article-title":"Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism","volume":"59","author":"Boulkroun","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0235","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/cen.12873","article-title":"Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype","volume":"83","author":"Scholl","year":"2015","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.molmed.2020.05.005_bb0240","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1210\/jc.2019-00531","article-title":"KCNJ5 somatic mutation is a predictor of hypertension remission after adrenalectomy for unilateral primary aldosteronism","volume":"104","author":"Vilela","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2020.05.005_bb0245","first-page":"1182","article-title":"Histopathological classification of cross-sectional image-negative hyperaldosteronism","volume":"102","author":"Yamazaki","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2020.05.005_bb0250","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.mce.2013.01.018","article-title":"KCNJ5 mutations in aldosterone producing adenoma and relationship with adrenal cortex remodeling","volume":"371","author":"Boulkroun","year":"2013","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.molmed.2020.05.005_bb0255","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.mce.2015.01.020","article-title":"Functional histopathological markers of aldosterone producing adenoma and somatic KCNJ5 mutations","volume":"408","author":"Fernandes-Rosa","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.molmed.2020.05.005_bb0260","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1210\/jc.2008-0594","article-title":"A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism","volume":"93","author":"Geller","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2020.05.005_bb0265","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrendo.2012.230","article-title":"Role of KCNJ5 in familial and sporadic primary aldosteronism","volume":"9","author":"Mulatero","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.molmed.2020.05.005_bb0270","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1073\/pnas.1121407109","article-title":"Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5","volume":"109","author":"Scholl","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2020.05.005_bb0275","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/HYPERTENSIONAHA.111.183996","article-title":"KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism","volume":"59","author":"Mulatero","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0280","doi-asserted-by":"crossref","first-page":"E1861","DOI":"10.1210\/jc.2013-2428","article-title":"a Novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III","volume":"98","author":"Monticone","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2020.05.005_bb0285","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000358197","article-title":"Discordant genotype-phenotype correlation in familial hyperaldosteronism type III with KCNJ5 gene mutation: a patient report and review of the literature","volume":"82","author":"Adachi","year":"2014","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.molmed.2020.05.005_bb0290","doi-asserted-by":"crossref","DOI":"10.1210\/en.2013-1944","article-title":"Pharmacology and pathophysiology of mutated KCNJ5 found in adrenal aldosterone producing adenomas","author":"Tauber","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmed.2020.05.005_bb0295","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1172\/JCI91733","article-title":"Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma","volume":"127","author":"Scholl","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2020.05.005_bb0300","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/HYPERTENSIONAHA.117.10226","article-title":"Macrolides blunt aldosterone biosynthesis: a proof-of-concept study in KCNJ5 mutated adenoma cells ex vivo","volume":"70","author":"Caroccia","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0305","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/08037051.2018.1436961","article-title":"Macrolides for KCNJ5-mutated aldosterone-producing adenoma (MAPA): design of a study for personalized diagnosis of primary aldosteronism","volume":"27","author":"Maiolino","year":"2018","journal-title":"Blood Press."},{"key":"10.1016\/j.molmed.2020.05.005_bb0310","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1161\/HYPERTENSIONAHA.113.01733","article-title":"Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas","volume":"63","author":"Williams","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0315","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1210\/en.2015-1466","article-title":"Pathogenesis of adrenal aldosterone-producing adenomas carrying mutations of the Na(+)\/K(+)-ATPase","volume":"156","author":"Stindl","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmed.2020.05.005_bb0320","doi-asserted-by":"crossref","first-page":"12706","DOI":"10.1073\/pnas.0505980102","article-title":"A third Na+-binding site in the sodium pump","volume":"102","author":"Li","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2020.05.005_bb0325","doi-asserted-by":"crossref","first-page":"L1","DOI":"10.1530\/ERC-13-0466","article-title":"Complementary somatic mutations of KCNJ5, ATP1A1, and ATP2B3 in sporadic aldosterone producing adrenal adenomas","volume":"21","author":"Dutta","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.molmed.2020.05.005_bb0330","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1210\/en.2015-2029","article-title":"Cellular pathophysiology of an adrenal adenoma-associated mutant of the plasma membrane Ca(2+)-ATPase ATP2B3","volume":"157","author":"Tauber","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmed.2020.05.005_bb0335","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1440-1681.1992.tb00462.x","article-title":"Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism","volume":"19","author":"Stowasser","year":"1992","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.molmed.2020.05.005_bb0340","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0960-0760(01)00097-8","article-title":"Familial hyperaldosteronism","volume":"78","author":"Stowasser","year":"2001","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.molmed.2020.05.005_bb0345","doi-asserted-by":"crossref","DOI":"10.1038\/srep19546","article-title":"Activating mutations in CTNNB1 in aldosterone producing adenomas","volume":"6","author":"Akerstrom","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2020.05.005_bb0350","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1504869","article-title":"Pregnancy, primary aldosteronism, and adrenal CTNNB1 mutations","volume":"373","author":"Teo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2020.05.005_bb0355","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1210\/jc.2018-00087","article-title":"Genetic characterization of GnRH\/LH-responsive primary aldosteronism","volume":"103","author":"Gagnon","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2020.05.005_bb0360","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1210\/jc.2016-1700","article-title":"PRKACA somatic mutations are rare findings in aldosterone-producing adenomas","volume":"101","author":"Rhayem","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2020.05.005_bb0365","doi-asserted-by":"crossref","first-page":"E900","DOI":"10.1210\/jc.2014-4167","article-title":"Primary aldosteronism and ARMC5 variants","volume":"100","author":"Zilbermint","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2020.05.005_bb0370","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/jhh.2015.98","article-title":"ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions","volume":"30","author":"Mulatero","year":"2016","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.molmed.2020.05.005_bb0375","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1056\/NEJMoa1304603","article-title":"ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome","volume":"369","author":"Assie","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2020.05.005_bb0380","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.emboj.7601934","article-title":"Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis","volume":"27","author":"Heitzmann","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.molmed.2020.05.005_bb0385","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1073\/pnas.0712000105","article-title":"TASK channel deletion in mice causes primary hyperaldosteronism","volume":"105","author":"Davies","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2020.05.005_bb0390","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1210\/en.2012-1527","article-title":"Task3 potassium channel gene invalidation causes low renin and salt-sensitive arterial hypertension","volume":"153","author":"Penton","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmed.2020.05.005_bb0395","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/HYPERTENSIONAHA.111.189662","article-title":"TASK-3 channel deletion in mice recapitulates low-renin essential hypertension","volume":"59","author":"Guagliardo","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0400","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/HYPERTENSIONAHA.118.11962","article-title":"Adrenal tissue-specific deletion of TASK channels causes aldosterone-driven angiotensin II-independent hypertension","volume":"73","author":"Guagliardo","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0405","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1210\/en.2013-1101","article-title":"Severe hyperaldosteronism in neonatal Task3 potassium channel knockout mice is associated with activation of the intraadrenal renin-angiotensin system","volume":"154","author":"Bandulik","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmed.2020.05.005_bb0410","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1093\/hmg\/dds333","article-title":"Dkk3 is a component of the genetic circuitry regulating aldosterone biosynthesis in the adrenal cortex","volume":"21","author":"El Wakil","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2020.05.005_bb0415","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12113-9","article-title":"Pathogenesis of hypertension in a mouse model for human CLCN2 related hyperaldosteronism","volume":"10","author":"G\u00f6ppner","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2020.05.005_bb0420","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13033-4","article-title":"Elevated aldosterone and blood pressure in a mouse model of familial hyperaldosteronism with ClC-2 mutation","volume":"10","author":"Schewe","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2020.05.005_bb0425","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1172\/JCI28764","article-title":"Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice","volume":"117","author":"Billet","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2020.05.005_bb0430","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1172\/JCI127429","article-title":"Chemogenetic activation of adrenocortical Gq signaling causes hyperaldosteronism and disrupts functional zonation","volume":"130","author":"Taylor","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2020.05.005_bb0435","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.1158\/0008-5472.CAN-05-0593","article-title":"Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors","volume":"65","author":"Tissier","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2020.05.005_bb0440","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1210\/en.2011-1205","article-title":"Aldosterone-producing adenoma formation in the adrenal cortex involves expression of stem\/progenitor cell markers","volume":"152","author":"Boulkroun","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmed.2020.05.005_bb0445","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/hmg\/ddt484","article-title":"WNT\/beta-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production","volume":"23","author":"Berthon","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2020.05.005_bb0450","doi-asserted-by":"crossref","DOI":"10.1186\/s12953-015-0063-8","article-title":"Proteomic characterization of adrenal gland embryonic development reveals early initiation of steroid metabolism and reduction of the retinoic acid pathway","volume":"13","author":"Dihazi","year":"2015","journal-title":"Proteome Sci."},{"key":"10.1016\/j.molmed.2020.05.005_bb0455","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50988-2","article-title":"Retinoic acid receptor alpha as a novel contributor to adrenal cortex structure and function through interactions with Wnt and Vegfa signalling","volume":"9","author":"El Zein","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2020.05.005_bb0460","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1210\/jc.2009-2010","article-title":"Adrenocortical zonation in humans under normal and pathological conditions","volume":"95","author":"Nishimoto","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2020.05.005_bb0465","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1161\/HYPERTENSIONAHA.110.158543","article-title":"Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism","volume":"56","author":"Boulkroun","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0470","doi-asserted-by":"crossref","first-page":"E4591","DOI":"10.1073\/pnas.1505529112","article-title":"Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands","volume":"112","author":"Nishimoto","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2020.05.005_bb0475","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.mce.2016.10.014","article-title":"Immunohistochemistry of aldosterone synthase leads the way to the pathogenesis of primary aldosteronism","volume":"441","author":"Nishimoto","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.molmed.2020.05.005_bb0480","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/HYPERTENSIONAHA.118.11086","article-title":"Cellular and genetic causes of idiopathic hyperaldosteronism","volume":"72","author":"Omata","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0485","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/HYPERTENSIONAHA.111.186205","article-title":"Mutations of the potassium channel KCNJ5 causing aldosterone-producing adenomas: one or two hits?","volume":"59","author":"Gomez-Sanchez","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0490","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/HYPERTENSIONAHA.115.05993","article-title":"Different somatic mutations in multinodular adrenals with aldosterone-producing adenoma","volume":"66","author":"Fernandes-Rosa","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.molmed.2020.05.005_bb0495","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1210\/jc.2016-1874","article-title":"Aldosterone-producing adenoma with a somatic KCNJ5 mutation revealing APC-dependent familial adenomatous polyposis","volume":"101","author":"Vouillarmet","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491420301349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491420301349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:19:52Z","timestamp":1761463192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491420301349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":99,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1471491420301349"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2020.05.005","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic and Genomic Mechanisms of Primary Aldosteronism","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2020.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}